| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | EG1; magicin; 1500003D12Rik |
| WB Predicted band size | 20 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于MED28抗体的3篇参考文献示例(注：内容为示例性概括，非真实文献)：
---
1. **"MED28 regulates epidermal growth factor receptor signaling in breast cancer cells"**
*Author: Sato et al. (2015)*
摘要：研究通过免疫共沉淀和Western blot技术，证实MED28抗体可特异性识别该亚基，并揭示其在乳腺癌细胞中通过调控EGFR信号通路影响肿瘤增殖。
2. **"The role of MED28 in maintaining vascular endothelial cell function"**
*Author: Zhang & Chen (2018)*
摘要：利用MED28抗体进行免疫荧光染色，发现MED28缺失导致内皮细胞迁移能力下降，提示其可能通过调控血管生成相关基因参与心血管疾病。
3. **"MED28 as a potential biomarker in hepatocellular carcinoma"**
*Author: Lee et al. (2020)*
摘要：通过组织芯片结合MED28抗体的免疫组化分析，证明MED28在肝癌组织中高表达，且与患者预后不良显著相关。
---
如需真实文献，建议在PubMed或Google Scholar中检索关键词“MED28 antibody” + “function”/“cancer”等，并筛选实验方法部分明确使用该抗体的研究。
MED28. a subunit of the Mediator complex, plays a critical role in transcriptional regulation by bridging transcription factors and RNA polymerase II. This evolutionarily conserved multi-protein complex modulates gene expression, impacting cellular processes like proliferation, differentiation, and stress responses. The MED28 protein (∼28 kDa) is encoded by the *MED28* gene and is involved in diverse pathways, including angiogenesis, cell cycle control, and signal transduction. Dysregulation of MED28 has been linked to cancers (e.g., breast, prostate), neurological disorders, and metabolic diseases, making it a research focus for mechanistic and therapeutic studies.
MED28 antibodies are essential tools for investigating its expression, localization, and interactions. They enable techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP). Commercially available antibodies are typically raised against specific epitopes (e.g., human MED28 N-terminal regions) and validated for cross-reactivity in models such as human, mouse, or rat. Challenges include ensuring specificity due to shared motifs across Mediator subunits. Recent studies highlight MED28's role in cancer progression—e.g., its overexpression in lung cancer correlates with poor prognosis, while knockdown suppresses tumor growth. These antibodies also aid in exploring MED28's non-canonical functions, including mitochondrial interactions or metabolic regulation. Proper validation (e.g., using siRNA-mediated knockdown controls) is critical to avoid off-target artifacts, ensuring reliable data in both basic and translational research contexts.
×
